Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer.

Area of Science:

• Immunology
• Oncology
• Prognostic Biomarkers

Background:

• Prognosis for metastatic castration-resistant prostate cancer (mCRPC) patients is variable.
• Blood-related factors, including immune cell profiles, influence patient outcomes.

Purpose of the Study:

• To investigate the prognostic significance of distinct whole blood immune cell components in mCRPC.
• To identify specific immune cell types that predict survival in chemotherapy-naive mCRPC patients.

Main Methods:

• Analysis of pre-treatment blood samples from 152 chemotherapy-naive mCRPC patients.
• Quantification of 22 immune cell types using CIBERSORT-X.
• Prognostic significance assessed via Kaplan-Meier and Cox regression analyses.

Main Results:

• Reduced CD8 T-cell proportions and elevated monocyte levels were associated with worse survival.
• High monocyte counts correlated with shorter median survival (32.2 vs. 40.3 months).
• Low CD8 T-cell levels were linked to shorter median survival (31.8 vs. 40.3 months).

Conclusions:

• Specific blood immune cell compositions, particularly CD8 T-cells and monocytes, hold significant prognostic value in mCRPC.
• These immune cell profiles could serve as potential biomarkers for mCRPC patient management.
• Further clinical trial exploration of these immune cell biomarkers is warranted.